Natco Pharma surged on Tuesday after the Intellectual Property Appellate Board (IPAB) upheld the grant of compulsory licence (CL) to the company, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation.
The order will pave the way for reduction in the prices of
costly life saving drugs. 
Shares ofthe companyare trading at Rs
444.45, up Rs 19.2, or 4.51% at the Bombay Stock Exchange (BSE) on
Tuesday at 9:43 a.m.
The scrip has touched an intra-day high of Rs 475 and low of Rs 443. The total volume of shares traded at the BSE is 9,803.In the earlier session, the shares gained 1.31%, or Rs 5.5, at Rs 425.25. Currently, the stock is trading down 12.02% from its 52-week high of Rs 505.20 and above 61.59% over the 52-week low of Rs 275.05.
Share Price Movement Period Pricein Rs Gain/(Loss) in Rs in % 1 Week 417.50 7.75 1.86 1 Month 458.30 (33.05) (7.21) 3 Months 434.15 (8.90) (2.05) 6 Months 345.20 80.05 23.19 1 Year 282.90 142.35 50.32 Note: Based on previous day closing price.
Post a Comment